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A B S T R A C T
Objective: To compare assessment of early pregnancy medication exposure using three methods of data collec-
tion.
Methods: Serum samples were obtained from 752 women participating in the PRegnancy and Infant
DEvelopment (PRIDE) Study before gestational week 17. For 52 women using medication at the date of blood
sampling according to Web-based questionnaires or pharmacy records, we analysed serum samples using un-
targeted liquid chromatography time-of-flight spectrometry.
Results: Medication was detected in 18 serum samples (35%). Medications taken orally for chronic conditions
reported in the questionnaire were detected in serum and vice versa. Pharmacy records did not identify addi-
tional exposed women, but missed exposure in 5 women mainly due to unavailability. We observed substantial
discordance between the three methods for inhaled medication, dermatological preparations, and medications
for short-term use, which went often undetected in serum.
Conclusions: It remains challenging to assess medication use in large-scale studies as no ‘gold standard’ is cur-
rently available.
1. Introduction
Medication use is very common during pregnancy, with prevalence
estimates generally exceeding 65% and increasing over the years [1–7].
Pregnant women use a wide variety of both prescription and over-the-
counter (OTC) medication, for both pregnancy-related conditions (e.g.,
nausea/vomiting, gastric reflux, hypertensive disorders) and conditions
unrelated to pregnancy (e.g., asthma, migraine, hay fever). Para-
doxically, insufficient data are currently available to completely char-
acterize the foetal risks of many medications commonly used during
pregnancy [8–10], hampering an evidence-based risk-benefit analysis
in clinical practice. Therefore, more research into the safety of
medication use during pregnancy is urgently needed.
Because of the ethical concerns of including pregnant women into
randomized controlled trials, we have to depend on post-marketing
epidemiologic studies to get more insight into the benefits and risks of
medication use during pregnancy. One of the major challenges of these
studies is valid exposure assessment: each method of data collection
comes with specific advantages and limitations. Many studies use self-
reported questionnaires or maternal interviews to assess medication use
during pregnancy. Although both prescription and OTC medication use
may be assessed, validation studies showed that medication use, par-
ticularly medication for short-term use, is underreported using these
methods of data collection [11–18]. Alternatively, routinely collected
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data on medication dispensing, for example prescription databases and
administrative claims databases, do not suffer from recall problems
[19]. These data sources, however, do not contain information on ac-
tual medication intake (i.e. adherence) and exact timing of medication
use, and often lack data on OTC medication and inpatient medication
exposures, leading to overreporting as well as underreporting of med-
ication use during pregnancy.
Biological monitoring or screening on medication may overcome
the potential for exposure misclassification associated with using self-
reported information or routinely collected data [20]. Due to the con-
straints related to this method of data collection, such as high costs,
increased potential for selection bias, and ethical and logistical chal-
lenges, this approach has rarely been used to assess medication use
during pregnancy. In the German ‘Lifestyle and Newborn Allergy Risk’
(LiNA) cohort study, untargeted liquid chromatography-tandem mass
spectrometry (LC–MS/MS) screening of urine samples collected in ge-
stational week 36 was used, detecting medication in 24% of the samples
[21,22]. Wolgast et al. used liquid chromatography with time-of-flight
mass spectrometry (LC-TOF-MS) to screen plasma samples of 200
pregnant women for medication use and compared the results to self-
reported data in the Swedish Medical Birth Registry [23]. Medication
use was detected by screening among 23% of women, of whom 86%
also self-reported the medication use. Of note, untargeted LC–MS/MS
and LC-TOF-MS analyses provide only information concerning a limited
time period after intake depending on the half-live of the medication
and do not cover all compounds.
As a gold standard for assessing medication use in epidemiologic
studies is unavailable, the aim of this study was to compare assessment
of medication exposure in early pregnancy using three methods of data
collection: self-administered Web-based questionnaires, pharmacy re-
cords, and screening of serum samples using untargeted LC-TOF-MS.
2. Methods
2.1. Study design and population
This study was embedded in the PRegnancy and Infant
DEvelopment (PRIDE) Study, an ongoing prospective cohort study
among pregnant women in The Netherlands [24]. In short, pregnant
women were invited for participation by their midwife or gynaecologist
just before or during the first prenatal care visit (usually gestational
weeks 8–10). After providing informed consent, participants completed
three Web-based questionnaires during pregnancy (at baseline and in
gestational weeks 17 and 34) and two questionnaires after giving birth
(2 and 6 months after the estimated date of delivery), followed by
biannual questionnaires during childhood. Paper-based questionnaires
were available upon request.
In addition, participants recruited by midwives from the Nijmegen
region were asked to donate 4 non-fasting 4.5 ml blood samples for
genetic and biochemical analyses, which were collected during the
routine blood sampling procedure in early pregnancy (preferably before
gestational week 13). From 3 blood samples, serum and plasma was
separated and subdivided into 7 units (4 serum, 2 plasma, and 1 ery-
throcytes). The fourth sample is whole blood for DNA extraction. All
blood samples were processed as shortly after blood draw as possible,
but in any case within 12 h, and stored at −80 °C until laboratory
analyses. For this study, we selected all PRIDE Study participants en-
rolled between July 2011 and September 2015 for whom blood samples
were available (n=752).
2.2. Web-based questionnaire
We used data from the first Web-based questionnaire that was
completed after the blood draw, which could be either the baseline
questionnaire or the second questionnaire at gestational week 17. In
both questionnaires, medication use was assessed using a
comprehensive indication-oriented structure as recommended in the
literature [25,26]. When pharmacological treatment for an indication
was reported, closed-ended questionnaires were administered to collect
information on the generic and brand name, exact timing and frequency
of use, and dose taken. In addition, we assessed whether medications
were used for conditions not included in the extensive list of indications
using open-ended questions. This questionnaire was recently validated,
with sensitivity ranging between 0.55 and 0.96 for medication for
chronic conditions, between 0.30 and 0.70 for medication for occa-
sional and short-term use, and between 0.60 and 0.89 for pregnancy-
related medication groups [18].
2.3. Pharmacy records
In the informed consent form, permission was asked to obtain
pharmacy records, which contained information on the name and
amount of the medications dispensed, daily dose, and intended time
period of use. The latter was derived from the date of dispensing and
registered stop date. In case the stop date was missing from the phar-
macy records, it was calculated from the amount dispensed and daily
dose. Pharmacy records were retrieved for the time period starting
1 year before pregnancy until 6 months after the estimated date of
delivery. In The Netherlands, pharmacy records are virtually complete
as all pharmacies use computerized dispensing records and almost ev-
eryone is registered with a single pharmacy [27]. However, when a
PRIDE Study participant reported to be registered at multiple phar-
macies, records were requested from all pharmacies listed.
2.4. Inclusion and exclusion criteria
We selected all participants who reported any prescription or OTC
medication use on the date of blood sampling in the Web-based ques-
tionnaire and/or were supposedly exposed to medication on the date of
blood sampling according to the pharmacy records. For many women,
the time period of medication use was not limited to the exact date of
blood sampling, but also included the days before sampling. Medication
that was taken as needed or with a frequency less than once per day was
excluded. Furthermore, we excluded women who were only exposed to
medication that cannot be detected in serum, including levothyroxine,
ferrous fumarate, urea-containing cream, and artificial tears. These
substances are either endogenous or undetectable by the analytical
method. Of note, the time of day of medication use is not captured in
the Web-based questionnaire nor in pharmacy records.
2.5. Serum analysis
The serum samples were pre-treated by protein precipitation and
subsequently analysed qualitatively by LC-QTOF-MS (Waters® Xevo G2-
S Quadrupole Time-of-Flight Mass Spectrometer), a high-resolution
technique based on the exact mass of the molecule [21–23]. The results
were compared with an in-house database of 1194 compounds (Sup-
plemental Table 1). As an internal control, a 4-component test mixture
(paracetamol, caffeine, verapamil, sulfadimethoxine) was used and
accepted based on a retention time deviation of ± 0.4min and a mass
tolerance of± 20mDa in positive mode and a retention time deviation
of ± 0.2 min and a mass tolerance of± 50mDa in negative mode,
respectively. The drugs were identified when there was a match based
on the same acceptance criteria as described above, on at least one
unique daughter fragment and a height of more than 1000 counts. All
positive samples identified had a mass tolerance of less than 10mDa
both in positive and negative mode.
2.6. Statistical analysis
For the women included in this study, exposure status based on the
three methods of data collection was first examined manually on the
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level of the individual medications. In an exploratory analysis, Kappa
statistics with 95% confidence intervals (CIs) were calculated to
quantify agreement between the methods of data collection for different
groups of medications with at least 5 exposed women, including any
medication use, any oral medication, medications taken orally for
chronic conditions, antihistamines, meclizine with or without pyr-
idoxine, inhalation medication, asthma medication, and dermatological
preparations. Statistical analyses were conducted using IBM SPSS
Statistics version 22 (IBM Corp, Armonk, NY, USA).
2.7. Ethical approval
The PRIDE Study was approved by the Committee on Research in-
volving Human Subjects region Arnhem-Nijmegen (CMO 2009/305).
Participation was voluntarily and all participants provided informed
consent.
3. Results
Of the 752 women for whom blood samples were available, 52
women (6.9%) potentially exposed to medications included in the in-
house database at the date of blood sampling were included in this
study: 19 with reported use of these medications on the date of blood
sampling in the questionnaire only (2.5%), 15 with medication ex-
posure according to pharmacy records only (2.0%), and 18 with posi-
tive reports in both data sources (2.4%). For 9 women included based
on the questionnaire data, pharmacy records were not available, be-
cause they did not provide consent to obtain records (n=2) or reported
an unknown pharmacy (n=3), or because the pharmacy did not return
the information requested (n=4). The mean age of the women in-
cluded was 30.5 years (SD 2.8), it was the first pregnancy for 24 women
(46%), and the mean gestational age at blood sampling was 11 weeks
(SD 2.1). For 25 women (48%), questionnaire information was obtained
from the baseline questionnaire (mean difference between blood sam-
pling and questionnaire administration 12 days [SD 17]); for the re-
maining 27 women, data were obtained from the second questionnaire
completed around gestational week 17 (mean difference between blood
sampling and questionnaire administration 39 days [SD 15]).
In total, we detected 9 different medications in 18 out of 52 samples
(35%): meclizine (n=7), mesalazine (n=3), paracetamol (n=2),
desloratadine, fexofenadine, paroxetine, prednisolone, sulfasalazine,
and venlafaxine. For 16 exposures, medication use was also self-re-
ported in the questionnaire (n = 12 [75%]) and/or abstracted from
pharmacy records (n=11 [69%]; Table 1). Medications taken orally
for chronic conditions detected in the serum samples (i.e. fexofenadine,
mesalazine, paroxetine, sulfasalazine, and venlafaxine; n=7) were also
reported in the questionnaire, but use would have been missed using
pharmacy records only for 5 of these medications, mostly due to un-
availability of pharmacy records (n=4). All 7 women who tested po-
sitive for meclizine in the serum sample filled a prescription for me-
clizine or the combination of meclizine and pyridoxine, mostly used for
pregnancy-related nausea. However, only 5 of these women (71%) re-
ported use of meclizine or meclizine/pyridoxine in the questionnaire
while 1 woman reported use of an unspecified medication for a gas-
trointestinal problem. In addition, for the 2 samples in which deslor-
atadine, a metabolite of loratadine, or prednisolone were detected, use
was not reported in the questionnaire whereas the pharmacy records
indicated use. For both samples with paracetamol, no reports of use
were obtained from the questionnaires or the pharmacy records.
In Table 2, medications are shown that were reported in the ques-
tionnaire and/or abstracted from pharmacy records but were not de-
tected by the LC-TOF-MS analysis in the serum samples. Inhaled med-
ications and dermatological preparations were reported relatively
frequently in the questionnaire (n=15), in pharmacy records (n=10),
or both (n=11), but were not detected in the serum samples at all.
Furthermore, reported use of oral antihistamines (questionnaire: n = 6;
pharmacy record: n=10; both: n=3) often went undetected in the
serum samples. Other medication exposures that were not detected in
the LC-TOF-MS analysis but were reported in the questionnaire in-
cluded paracetamol (n=2), amoxicilline/clavulanic acid, omeprazole,
and prednisone, whereas use of amoxicillin (n=2) was obtained from
pharmacy records only. Supplemental Table 2 shows the medication
exposure information from the three methods of data collection for all
women included in this study.
The Kappa statistics for agreement between the pairs of methods of
data collection for the different medication groups are shown in
Table 3. The Kappa statistics ranged between 0.00 (inhalation medi-
cation or dermatological preparation for questionnaire or pharmacy
record versus serum screening) and 0.91 (95% CI 0.74–1.00; medica-
tion taken orally for chronic conditions for questionnaire versus serum
screening). For medications taken orally, including the subgroups,
agreement between the questionnaire and serum screening seemed to
be higher compared to the other combinations of data collection
methods.
4. Discussion
In this exploratory study, screening of 52 serum samples through
untargeted LC-TOF-MS detected medications in only 35% of pregnant
women who used medication on the date of sampling according to a
Web-based questionnaire and/or pharmacy records. All medications
detected in the serum samples were reported in the questionnaire and/
or abstracted from the pharmacy records, with the exception of 2
women for whom additional exposure to paracetamol was detected.
Medications taken orally for chronic conditions reported in the ques-
tionnaire were also detected in the serum samples, whereas pharmacy
records did not yield additional exposures for these medications, but
missed several truly exposed women mainly due to unavailability.
Pregnancy-related medications detected in the serum samples were in
accordance with pharmacy records, but were not correctly reported by
2 women. We observed substantial discordance between the three
modes of data collection for inhaled medication, dermatological pre-
parations, and medications for short-term use, which could often not be
Table 1
Medication use detected by LC-TOF-MS screening of serum samples of pregnant
women and medication use according to Web-based questionnaires and phar-
macy records.
Subject ID Detected in serum Questionnaire Pharmacy record
25 Desloratadinea Not reported Loratadine
45 Fexofenadine Fexofenadine Fexofenadine
7 Meclizine Not reported Meclizine
20 Meclizine Unspecified medication
for GI problem
Meclizine/
pyridoxine
27 Meclizine Meclizine/pyridoxine Meclizine/
pyridoxine
44 Meclizine Meclizine/pyridoxine Meclizine/
pyridoxine
46 Meclizine Meclizine Meclizine
50 Meclizine Meclizine/pyridoxine Meclizine/
pyridoxine
52 Meclizine Meclizine/pyridoxine Meclizine/
pyridoxine
32 Mesalazine Mesalazine Not available
34 Mesalazine Mesalazine Not available
36 Mesalazine Mesalazine Not available
11 Paracetamolb Not reported Not registered
51 Paracetamolb Not reported Not registered
3 Paroxetine Paroxetine Not registered
16 Prednisolone Not reported Prednisolone
35 Sulfasalazine Sulfasalazine Not available
49 Venlafaxine Venlafaxine Venlafaxine
a Metabolite of loratadine.
b Available over-the-counter.
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detected in serum samples with LC-TOF-MS.
Although biological monitoring or screening is often held in high
regard for exposure assessment in medical studies, untargeted LC-TOF-
MS analysis of a single serum sample seemed to miss the majority of
medication exposures among women in early pregnancy. This analy-
tical method might not be sufficiently sensitive to detect medications
with low serum concentrations, including inhalation medication and
dermatological preparations. However, these types of medications were
included in the compound library (Supplemental Table 1) and may be
detected with mass spectrometry [28–30]. Medications with a short
half-life, such as amoxicilline (1–1.5 h), paracetamol (2.7 h), salbu-
tamol (4 h), and meclizine (6 h), may not be detected by LC-TOF-MS
analysis when the time span between intake and blood sampling is too
long. We did not record the moment medication was taken and the time
of blood sampling, however. Other matrices, such as urine and maternal
hair [31], provide a broader detection time window for monitoring
medication use, but are currently not available in the PRIDE Study.
Furthermore, overestimation of medication intake due to non-ad-
herence (pharmacy records) or irregular use (pharmacy records and
questionnaires) may explain some of the discrepancies between the
methods of data collection.
The prevalence of medication use in our population (6.9%) may
seem low compared to other studies on first trimester medication use
(> 30%) [1–4,6,7]. For the current study, however, we only de-
termined medication use on the exact day of blood sampling instead of
in the first 13 weeks of pregnancy. Due to differences in the selection of
samples for biological screening and possibly in the analytical ap-
proach, the prevalence of medication use among women included in
this study (35%) was higher compared to the other two settings in
which screening among pregnant women was applied (23–24%)
[21–23]. In these studies, analgesics were often detected, whereas in
our study, paracetamol was detected in only 2 samples. Meclizine,
which is used to treat nausea and vomiting of pregnancy, was the most
common medication detected in our serum samples collected in early
pregnancy. Differences in gestational week of sampling and country
may explain these differences, particularly for the studies conducted in
the German LiNA cohort, in which urine was collected in gestational
week 36.
The major strength of using PRIDE Study data to compare methods
of data collection for assessing medication use during pregnancy is the
availability of a validated Web-based questionnaire [18]. Although this
questionnaire is prone to some underreporting of medication use, par-
ticularly for medication for short-term use, the sensitivity is higher
compared to paper-based questionnaires. Through this questionnaire,
the exact dates of medication use were gathered, which was often im-
possible in previous studies using more traditional modes of data col-
lection. Whereas other studies evaluated only two methods of data
collection, we were able to compare three different methods simulta-
neously, although pharmacy records were not available for all women
included. Other limitations of this study include the relatively small
Table 2
Medication exposure according to the Web-based questionnaires and/or pharmacy records undetected by LC-TOF-MS screening of serum samples of pregnant women
(n=52).
Questionnaire and pharmacy record Questionnaire only Pharmacy record only
Pharmacy record available Pharmacy record unavailable
Medication n Medication n Medication n Medication n
Beclometasone 4 Beclometasone 3 Budesonide 3 Fluticasone 4b
Clemastine 2 Aciclovira 2 Paracetamola 2 Levocetirizine 3c
Salbutamol 2 Cetirizinea 2 Xylometazolinea 2 Loratadinea 3
Budesonide 1 Levocetirizine 2 Beclometasone 1 Amoxicillin 2
Clobetasone 1 Amoxicillin/clavulanic acid 1 Beclometasone 2
Fluticasone 1 Budesonide 1 Meclizine 2
Formoterol 1 Clemastine 1 Mometasone 2
Loratadinea 1 Formoterol/beclometasone 1 Budesonide 1
Mometasone 1 Levocabastine 1 Desloratadine 1
Loratadinea 1 Hydrocortisone 1
Omeprazolea 1 Meclizine/pyridoxine 1
Prednisone 1
Salbutamol 1
Triamcinolone/salicylic acid 1
Total n 14 Total n 19 Total n 8 Total n 22
a Available over-the-counter.
b 1 woman reported use of an unspecified respiratory medication in the questionnaire.
c 1 woman reported use of an unspecified anti-allergy medication in the questionnaire.
Table 3
Agreement between the three methods of data collection for medication use in early pregnancy among women participating in the PRIDE Study (n= 52).
Medication group Kappa statistic (95% CI)
Questionnaire versus pharmacy record Questionnaire versus serum screening Pharmacy record versus serum screening
Any medication NAa 0.24 (0.05-0.43) 0.10 (-0.09-0.29)
Any medication taken orally 0.14 (-0.14-0.42) 0.45 (0.21-0.69) 0.37 (0.13-0.61)
For chronic conditions NAb 0.91 (0.74-1.00) NAb
Antihistamines 0.34 (0.09-0.59) 0.54 (0.27-0.81) 0.43 (0.21-0.65)
Meclizine ± pyridoxine 0.61 (0.32-0.90) 0.81 (0.56-1.00) 0.78 (0.54-1.00)
Any inhalation medication 0.31 (0.00-0.62) 0.00 0.00
Asthma medication 0.63 (0.24-1.00) 0.00 0.00
Any dermatological preparation 0.45 (0.00-0.90) 0.00 0.00
a Not applicable: cannot be calculated due to the inclusion and exclusion criteria.
b Not applicable: less than 5 exposed subjects due to unavailability of pharmacy records.
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sample size and the inability to determine serum concentrations for all
medications. The latter may provide more insight into the pharmaco-
kinetic characteristics among pregnant women, as well as into foetal
exposure. Due to financial constraints, we could not analyse all serum
samples, but the inclusion criteria (i.e. medication use reported in the
questionnaire and/or recorded in the pharmacy record for the date of
blood sampling), may have biased the estimated agreement between
the methods of data collection. The inability to include women who did
not use medication at all led to underestimation of the Kappa statistics,
whereas the inability to include women who did not report medication
use and did not use medication according to the pharmacy records, but
would have been tested positive in the serum screening, may have led
to overestimation of the kappa statistic. However, if medication cannot
be detected in women who are likely to be exposed (i.e. the population
included in this study), it is questionable whether analysing all women
would yield a substantial number of additional exposures.
The results of this study confirm that currently no ‘gold standard’ is
available for assessing medication use during pregnancy. It remains
challenging if not impossible to determine the true exposure status in
case of conflicting sources of information. Screening with LC-TOF-MS
analysis using a single serum sample seemed unable to detect use of
particular medications compared to the more traditional methods of
self-reported questionnaires and pharmacy records, which are both
prone to over- and underreporting. Novel methods of data collection,
such as mobile applications to daily record medication intake, may
improve exposure assessment of medication use during pregnancy [32].
Funding
This study was supported by the Netherlands Organisation for
Health Research and Development (ZonMw; grant number
836012001).
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in the
online version, at https://doi.org/10.1016/j.reprotox.2019.01.002.
References
[1] M.M. Werler, A.A. Mitchell, S. Hernandez-Diaz, M.A. Honein, Use of over-the-
counter medications during pregnancy, Am. J. Obstet. Gynecol. 193 (2005)
771–777.
[2] M.K. Bakker, J. Jentink, F. Vroom, P.B. Van Den Berg, H.E.K. De Walle, L.T.W. De
Jong-Van Den Berg, Drug prescription patterns before, during and after pregnancy
for chronic, occasional and pregnancy-related drugs in the Netherlands, BJOG 113
(2006) 559–568.
[3] A. Engeland, J.G. Bramness, A.K. Daltveit, M. Rønning, S. Skurtveit, K. Furu,
Prescription drug use among fathers and mothers before and during pregnancy. A
population-based cohort study of 106,000 pregnancies in Norway 2004-2006, Br. J.
Clin. Pharmacol. 65 (2008) 653–660.
[4] A.A. Mitchell, S.M. Gilboa, M.M. Werler, K.E. Kelley, C. Louik, S. Hernández-Díaz,
Medication use during pregnancy, with particular focus on prescription drugs:
1976-2008, Am. J. Obstet. Gynecol. 205 (2011) 51–58.
[5] A. Lupattelli, O. Spigset, M.J. Twigg, K. Zagorodnikova, A.C. Mårdby, M.E. Moretti,
et al., Medication use in pregnancy: a cross-sectional, multinational web-based
study, BMJ Open 4 (2014) e004365.
[6] K. Palmsten, S. Hernández-Díaz, C.D. Chambers, H. Mogun, S. Lai, T.P. Gilmer,
et al., The most commonly dispensed prescription medications among pregnant
women enrolled in the US Medicaid program, Obstet. Gynecol. 126 (2015)
465–473.
[7] K. Smolina, G.E. Hanley, B. Mintzes, T.F. Oberlander, S. Morgan, Trends and de-
terminants of prescription drug use during pregnancy and postpartum in British
Columbia, 2002-2011: a population-based cohort study, PLoS One 10 (2015)
e0128312.
[8] M.P. Adam, J.E. Polifka, J.M. Friedman, Evolving knowledge of the teratogenicity
of medications in human pregnancy, Am. J. Med. Genet. C Semin. Med. Genet. 157
(2011) 175–182.
[9] P.G. Thorpe, S.M. Gilboa, S. Hernandez-Diaz, J. Lind, J.D. Cragan, G. Briggs, et al.,
Medications in the first trimester of pregnancy: most common exposures and critical
gaps in understanding fetal risk, Pharmacoepidemiol. Drug Saf. 22 (2013)
1013–1018.
[10] M.M.H.J. Van Gelder, L.T.W. de Jong-van den Berg, N. Roeleveld, Drugs associated
with teratogenic mechanisms. Part II: a literature review of the evidence on human
risks, Hum. Reprod. 29 (2014) 168–183.
[11] P.C. De Jong, A.A. Huijsmans, H.E. Nienhuis, W.S. Nijdam, G.A. Zielhuis,
T.K. Eskes, Validation of a questionnaire on medical drug use during pregnancy,
Am. J. Epidemiol. 134 (1991) 998–1002.
[12] L.T.W. De Jong-van den Berg, C.M. Waardenburg, F.M. Haaijer-Ruskamp,
M.N.G. Dukes, H. Wesseling, Drug use in pregnancy: a comparative appraisal of
data collecting methods, Eur. J. Clin. Pharmacol. 45 (1993) 9–14.
[13] D.J. Newport, P.A. Brennan, P. Green, D. Ilardi, T.H. Whitfield, N. Morris, et al.,
Maternal depression and medication exposure during pregnancy: comparison of
maternal retrospective recall to prospective documentation, BJOG 115 (2008)
681–688.
[14] P. Sarangarm, B. Young, W. Rayburn, P. Jaiswal, M. Dodd, S. Phelan, et al.,
Agreement between self-report and prescription data in medical records for preg-
nant women, Birth Defects Res. A Clin. Mol. Teratol. 94 (2012) 153–161.
[15] M.M.H.J. Van Gelder, I.A.L.M. van Rooij, H.E.K. de Walle, N. Roeleveld,
M.K. Bakker, Maternal recall of prescription medication use during pregnancy using
a paper-based questionnaire: a validation study in the Netherlands, Drug Saf. 36
(2013) 43–54.
[16] F.E. Pisa, A. Casetta, E. Clagnan, E. Michelesio, L. Vecchi Brumatti, F. Barbone,
Medication use during pregnancy, gestational age and date of delivery: agreement
between maternal self-reports and health database information in a cohort, BMC
Pregnancy Childbirth 15 (2015) 310.
[17] A.C. Sundermann, K.E. Hartmann, S.H. Jones, E.S. Torstenson, D.R. Velez Edwards,
Validation of maternal recall of early pregnancy medication exposure using pro-
spective diary data, Ann. Epidemiol. 27 (2017) 135–139 e2.
[18] M.M.H.J. Van Gelder, S. Vorstenbosch, B. te Winkel, E.P. van Puijenbroek,
N. Roeleveld, Using web-based questionnaires to assess medication use during
pregnancy: a validation study in 2 prospectively enrolled cohorts, Am. J. Epidemiol.
187 (2018) 326–336.
[19] S.E. Andrade, A. Bérard, H.M.E. Nordeng, M.E. Wood, M.M.H.J. van Gelder, S. Toh,
Administrative claims data versus augmented pregnancy data for the study of
pharmaceutical treatments in pregnancy, Curr. Epidemiol. Rep. 4 (2017) 106–116.
[20] T.E. Arbuckle, Maternal-infant biomonitoring of environmental chemicals: the
epidemiologic challenges, Birth Defects Res. A Clin. Mol. Teratol. 88 (2010)
931–937.
[21] H. Hoeke, S. Roeder, T. Bertsche, I. Lehmann, M. Borte, M. von Bergen, et al.,
Monitoring of drug intake during pregnancy by questionnaires and LC-MS/MS drug
urine screening: evaluation of both monitoring methods, Drug Test. Anal. 7 (2015)
695–702.
[22] H. Hoeke, S. Roeder, T. Bertsche, M. Borte, M. von Bergen, D.K. Wissenbach,
Assessment of maternal drug intake by urinary bio monitoring during pregnancy
and postpartally until the third perinatal year, Pharmacoepidemiol. Drug Saf. 25
(2016) 431–437.
[23] E. Wolgast, A. Josefsson, M. Josefsson, C. Lilliecreutz, M. Reis, Drug use in pregnant
women-a pilot study of the coherence between reported use of drugs and presence
of drugs in plasma, Eur. J. Clin. Pharmacol. 74 (2018) 535–539.
[24] M.M.H.J. Van Gelder, R.W. Bretveld, J. Roukema, M. Steenhoek, J. van Drongelen,
M.E.A. Spaanderman, et al., Rationale and design of the PRegnancy and Infant
DEvelopment (PRIDE) Study, Paediatr. Perinat. Epidemiol. 27 (2013) 34–43.
[25] A.A. Mitchell, L.B. Cottler, S. Shapiro, Effect of questionnaire design on recall of
drug exposure in pregnancy, Am. J. Epidemiol. 123 (1986) 670–676.
[26] O.H. Klungel, A. de Boer, A.H.P. Paes, R.M.C. Herings, J.C. Seidell, A. Bakker,
Influence of question structure on the recall of self-reported drug use, J. Clin.
Epidemiol. 53 (2000) 273–277.
[27] H.G. Leufkens, J. Urquhart, Automated pharmacy records linkage in the
Netherlands, in: B.L. Strom (Ed.), Pharmacolepidemiology, 4th edn., John Wiley &
Sons Ltd, Chichester, 2005, pp. 311–322.
[28] J. Martens, Determination of loratadine and pheniramine from human serum by gas
chromatography-mass spectrometry, J. Chromatogr. B Biomed. Appl. 673 (1995)
183–188.
[29] H. Möllmann, M. Wagner, B. Meibohm, G. Hochhaus, J. Barth, R. Stöckmann, et al.,
Pharmacokinetic and harmacodynamics evaluation of fluticasone propionate after
inhaled administration, Eur. J. Clin. Pharmacol. 53 (1998) 459–467.
[30] D. Schimek, R. Rami, K.A. Francesconi, M. Bodenlenz, F. Sinner, Quantification of
acyclovir in dermal interstitial fluid and human serum by ultra-high-performance
liquid-high-resolution tandem mass spectrometry for topical bioequivalence eva-
luation, Biomed. Chromatogr. 32 (2018) e4194.
[31] T. Gray, M. Huestis, Bioanalytical procedures for monitoring in utero drug ex-
posure, Anal. Bioanal. Chem. 388 (2007) 1455–1465.
[32] O. Stephansson, How to improve information on medication exposure during
pregnancy, Paediatr. Perinat. Epidemiol. 32 (2018) 78–80.
M.M.H.J. van Gelder et al. Reproductive Toxicology 84 (2019) 93–97
97
